Individualized drug dosage in patients treated with continuous hemofiltration

Kidney International, Supplement

Volumn 56, Issue 72, 1999, Pages

  Keller, Frieder ^a   Böhler, Joachim ^a   Czock, David ^a   Zellner, Dietmar ^a   Mertz, Andreas K H ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Creatinine clearance; Drug monitoring; High flux hemofiltration; Intensive care

Indexed keywords

ARTICLE; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DRUG CLEARANCE; HEMOFILTRATION; INTENSIVE CARE; KIDNEY FAILURE; PRIORITY JOURNAL; TREATMENT PLANNING; BLOOD; DRUG DETOXIFICATION; HUMAN; PHARMACOKINETICS; REVIEW;

CREATINE;

CREATINE; HEMOFILTRATION; HUMANS; KIDNEY FAILURE; METABOLIC DETOXICATION, DRUG; PHARMACOKINETICS;

EID: 0038201622     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. JOY MS, MATZKE GR, FRYE RF, PALEVSKY PM. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis 31:1019-1027, 1998
2. LEYPOLDT JK, GILSON JF, BLINDAUER KM, CIIEUNG AK. Macromolecule adsorption to hemodialysis membranes depends on molecular size. Blood Purif 10:53-60, 1992
3. LAU AH, KRONFOL NO. Effect of continuous hemofiltration on phenytoin elimination. Ther Drug Monit 16:53-57, 1994
4. KELLER F, CZOCK D. Pharmacokinetic studies in volunteers with renal impairment. lnt J Clin Pharmacol Ther 36:594-598, 1998
5. CLARK WR, MUELLER BA, KRAUS MA, MACIAS WL. Quantification of creatinine kinetic parameters in patients with acute renal failure. Kidney Int 54:554-560, 1998
6. THALHAMMER F, SCHENK P, BURGMANN H, EL MENYAWI I, HOLLENSTEIN UM, ROSENKRANZ AR, SUNDER PLASSMANN G, BREYER S, RATHEISER K. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 42:2417-2420, 1998
7. TEGEDER I, BREMER F, OELKERS R, SCHOBEL H, SCHUTTLER J, BRUNE K, GEISSLINGER G. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemolher 41:2640-2645, 1997
8. ALLAOUCHICHE B, BREILH D, JAUMAIN H, GAILLARD B, RENARD S, SAUX MC. Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration. Antimicrob Agents Chemolher 41. 2424-2427, 1997
9. VAN DER WERFTS, MULDER PO, ZIJLSTRA JG, UGES DR, STEGEMAN ÇA. Pharmacokinetics of piperacillin and tazobactani in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 23:873-877, 1997
10. LOUR JW, WILLSKY GR, ACARA MA. Renal drug metabolism. Pharmacol Rev 50:107-141, 1998
11. NOUAILLE-DEGORCE B, VEAU C, DAUTREY S, TOD M, LAOUARI D, CARBON C, FARINOTTI R. Influence of renal failure on ciprofloxacin pharmacokinetics in rats. Antimicrob Agents Chemolher 42:289-292, 1998
12. MUELLER BA, SCARIM SK, MACIAS WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis 21:172-179, 1993
13. STORY DA, RONCO C, BELLOMO R. Trace element and vitamin concentrations and losses in critically ill patients treated with continuous venovenous hemofiltration. Crit Care Med 27:220-223, 1999
14. DAVIES SP, REAVELEY DA, BROWN EA, Kox WJ. Amino acid clearances and daily losses in patients with acute renal failure treated by continuous arteriovenous hemodialysis. Crit Care Med 19:1510-1515, 1991
15. HOLFORD N (editor). Clinical Pharmacokinetics. Drug Data Handbook (3rd ed). Auckland, Adis, 1998